Treats acute, uncomplicated influenza type A and B infections. Sold as Relenza. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Zanamivir (sold as Relenza), first approved Jul 26, 1999, with 3 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Relenza | Part D | $18K | +36% | 168 |
| A/Texas Flu ChallengeInfluenza · Emory University | Phase 1 | Recruiting | Dec 31, 2024 |
| A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic InfluenzaInfluenza, Influenza, Human · University of Oxford | Phase 2 | Recruiting | Dec 13, 2022 |
| Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)Dengue Fever · George Washington University | Phase 2 | Recruiting | Oct 22, 2020 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jul 26, 1999 | RelenzaNDA 21036 · New molecular entity | Glaxosmithkline | 25 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Glaxosmithkline